In some areas, its clear that GLP-1s have clearly strong, positive effects on an individuals health and well-being (i.e., diabetes, obesity), and in other areas, its not yet clear, but we may soon find the same (i.e., neurological diseases)
The honest answer is that we don't know for certain
Diabetes Relevance For type 2 diabetes, CagriSema has an intuitive path because one component is semaglutide, an established GLP-1 therapy, and the amylin component may improve appetite and post-prandial glucose handling
The results indicate a protective role of GSTP1 by enhancing GSH-conjugation, which might lead to a reduced protein modification, and suggest a second protective role by interfering with the unfolded protein response, thereby preventing apoptosis
Los efectos secundarios de los agonistas GLP-1 estn generalmente relacionados con la dosis, siendo ms frecuentes y severos con dosis ms altas